SCHEMBL1565595

SCHEMBL1565595

O=C(Nc1nccs1)N(CCc1cccs1)Cc1ccc(Cl)c(Cl)c1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.47
LMNA P02545 3/20 0.43
NPC1 O15118 2/20 0.43
RAB9A P51151 2/20 0.43
FFAR2 O15552 1/20 0.43
CYP3A4 P08684 1/20 0.43
CYP2D6 P10635 1/20 0.43
CYP2C19 P33261 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.43
TSHR P16473 2/20 0.42
HTT P42858 1/20 0.42
NPSR1 Q6W5P4 1/20 0.42
KDM4E B2RXH2 4/20 0.42
MEN1 O00255 2/20 0.42
ALDH1A1 P00352 2/20 0.42
KMT2A Q03164 2/20 0.42
MGAM O43451 2/20 0.42
GAA P10253 2/20 0.42
SI P14410 2/20 0.42
MGAM2 Q2M2H8 2/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2654801 0.83 MAPT (0.49) MAPTFFAR2L3MBTL1TSHRKDM4E
SCHEMBL1564971 0.80 MAPT (0.50) MAPTLMNAFFAR2TSHRKDM4E
SCHEMBL1565355 0.79 TDP1 (0.56) MAPTNPC1RAB9ATSHRMEN1
SCHEMBL1565282 0.77 POLB (0.48) MAPTLMNAFFAR2TSHRHTT
SCHEMBL1566757 0.73 MAPT (0.47) MAPTLMNANPC1RAB9AFFAR2
SCHEMBL1565138 0.73 MAPT (0.45) MAPTLMNANPC1RAB9AFFAR2
SCHEMBL1565806 0.73 MAPT (0.49) MAPTFFAR2TSHRHTTKDM4E
SCHEMBL2651656 0.73 FFAR2 (0.73) MAPTLMNAFFAR2CYP3A4CYP2D6
SCHEMBL1565141 0.71 MAPT (0.50) MAPTLMNANPC1RAB9AFFAR2
SCHEMBL1565387 0.69 MAPT (0.52) MAPTLMNANPC1RAB9AFFAR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2305648-A1 Amide derivatives useful as glucokinase activators Novo Nordisk A/S (DK) 2011-04-06 EP disclosed
EP-2305648-A1 Amide derivatives useful as glucokinase activators Novo Nordisk A/S (DK) 2011-04-06 EP disclosed
EP-1458382-A1 AMIDE DERIVATIVES AS GK ACTIVATORS NOVO NORDISK A/S (DK) 2004-09-22 EP disclosed
US-20030171411-A1 Amide derivatives as therapeutic agents NOVO NORDISK A/S (DK) 2003-09-11 US disclosed
WO-2003055482-A1 AMIDE DERIVATIVES AS GK ACTIVATORS NOVO NORDISK A/S (DK) 2003-07-10 WO disclosed
WO-2003055482-A1 AMIDE DERIVATIVES AS GK ACTIVATORS NOVO NORDISK A/S (DK) 2003-07-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030171411-A1 Amide derivatives as therapeutic agents GK, GCKR, GCK MAPT 4194/4885LMNA 3743/4885NPC1 271/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.